EVT-401 is under clinical development by Evotec and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect EVT-401’s likelihood of approval (LoA) and phase transition for Inflammation took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their EVT-401 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
EVT-401 is under development for the treatment of inflammatory disease and rheumatoid arthritis. The drug candidate is administered through oral route. EVT-401 is a small molecule targeting P2X7 receptor.
Evotec is a drug discovery alliance and development partnership company. It discovers and develops small molecule drugs spanning various conditions areas such as oncology, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides drug discovery services such as target identification and validation, hit identification, sample management, in vitro pharmacology services, integrated CMC, and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Alderley Park, the UK; Gottingen and Munich, Germany; Orth an der Donau, Austria; Branford, Princeton and Watertown, the US; Verona, Italy; and Toulouse and Lyon, France. Evotec is headquartered in Hamburg, Germany.
Quick View EVT-401 LOA Data
|Highest Development Stage|